
Sarah L Gorst

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6137210/publications.pdf Version: 2024-02-01



SADAH L CODST

#	Article	IF	CITATIONS
1	The COMET Handbook: version 1.0. Trials, 2017, 18, 280.	1.6	1,128
2	Core Outcome Set-STAndards for Development: The COS-STAD recommendations. PLoS Medicine, 2017, 14, e1002447.	8.4	427
3	Core Outcome Set–STAndards for Reporting: The COS-STAR Statement. PLoS Medicine, 2016, 13, e1002148.	8.4	404
4	Core Outcome Set-STAndardised Protocol Items: the COS-STAP Statement. Trials, 2019, 20, 116.	1.6	145
5	Choosing Important Health Outcomes for Comparative Effectiveness Research: An Updated Review and User Survey. PLoS ONE, 2016, 11, e0146444.	2.5	113
6	Choosing important health outcomes for comparative effectiveness research: 5th annual update to a systematic review of core outcome sets for research. PLoS ONE, 2019, 14, e0225980.	2.5	82
7	Improving the relevance and consistency of outcomes in comparative effectiveness research. Journal of Comparative Effectiveness Research, 2016, 5, 193-205.	1.4	74
8	COS-STAR: a reporting guideline for studies developing core outcome sets (protocol). Trials, 2015, 16, 373.	1.6	64
9	Choosing Important Health Outcomes for Comparative Effectiveness Research: An Updated Review and Identification of Gaps. PLoS ONE, 2016, 11, e0168403.	2.5	57
10	Choosing important health outcomes for comparative effectiveness research: 4th annual update to a systematic review of core outcome sets for research. PLoS ONE, 2018, 13, e0209869.	2.5	52
11	Choosing important health outcomes for comparative effectiveness research: An updated systematic review and involvement of low and middle income countries. PLoS ONE, 2018, 13, e0190695.	2.5	52
12	Choosing important health outcomes for comparative effectiveness research: 6th annual update to a systematic review of core outcome sets for research. PLoS ONE, 2021, 16, e0244878.	2.5	41
13	Assessing the relevance and uptake of core outcome sets (an agreed minimum collection of outcomes) Tj ETQq1	1 0,7843 1.9	14 rgBT /Ove
14	Use of core outcome sets was low in clinical trials published in major medical journals. Journal of Clinical Epidemiology, 2022, 142, 19-28.	5.0	33
15	Methods used in the selection of instruments for outcomes included in core outcome sets have improved since the publication of the COSMIN/COMET guideline. Journal of Clinical Epidemiology, 2020, 125, 64-75.	5.0	30
16	Review finds core outcome set uptake in new studies and systematic reviews needs improvement. Journal of Clinical Epidemiology, 2022, 150, 154-164.	5.0	30
17	More than half of systematic reviews have relevant core outcome sets. Journal of Clinical Epidemiology, 2021, 136, 168-179.	5.0	24
18	Incorporating patients' perspectives into the initial stages of core outcome set development: a rapid review of qualitative studies of type 2 diabetes. BMJ Open Diabetes Research and Care, 2019, 7, e000615.	2.8	22

SARAH L GORST

#	Article	IF	CITATIONS
19	Patient-reported outcome measures in core outcome sets targeted overlapping domains but through different instruments. Journal of Clinical Epidemiology, 2021, 136, 26-36.	5.0	17
20	Inclusion of participants from low-income and middle-income countries in core outcome sets development: a systematic review. BMJ Open, 2021, 11, e049981.	1.9	13
21	Ensuring young voices are heard in core outcome set development: international workshops with 70 children and young people. Research Involvement and Engagement, 2020, 6, 19.	2.9	12
22	Representation of published core outcome sets for research in regulatory guidance: protocol. HRB Open Research, 2021, 4, 45.	0.6	4
23	Representation of published core outcome sets for research in regulatory guidance: protocol. HRB Open Research, 2021, 4, 45.	0.6	3
24	Representation of published core outcome sets for research in regulatory guidance: protocol. HRB Open Research, 0, 4, 45.	0.6	3
25	Scout - sarcoidosis outcomes taskforce. A systematic review of outcomes to inform the development of a core outcome set for pulmonary sarcoidosis. Sarcoidosis Vasculitis and Diffuse Lung Diseases, 2021, 38, e2021034.	0.2	2
26	A review of the Cochrane COVID-19 Study Register reveals inconsistency in the choice and measurement of SARS-CoV-2 infection outcomes in prevention trials. F1000Research, 0, 10, 426.	1.6	0